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Abstract
Objective: Ankaferd® Blood Stopper (ABS) is an herbal extract that has historically been used as a 
hemostatic agent in traditional Turkish medicine. ABS is comprised of a standardized herbal mixture 
of T. vulgaris, G. glabra, V. vinifera, A. officinarum, and U. dioica. ABS’s basic mechanism of action 
is the formation of an encapsulated protein web, which represents the focal point for vital erythrocyte 
masses. The hemostatic effects of ABS have been observed in vitro and in vivo. ABS was registered as 
a  hemostatic  agent  for  external  hemorrhages  and  dental  bleeding  following  phase  I  randomized, 
double-blind crossover placebo-controlled clinical research, and safety and efficacy reports. In terms 
of the potential use of ABS, transcription factors may be novel factors that play a role in the hemo-
static and other pleiotropic effects of ABS. 
Materials and Methods: Hence, the present study aimed to investigate the effects of ABS on endothe-
lium, and possible transcription factor changes in HUVEC (human umbilical vein endothelial cells) 
and the erythrocyte membrane profile. 
ABS (5 μL and 50 μL) was administered to HUVEC (in 75 cm2; ~75% fullness) for 5 min and 15 min. 
Results: ABS caused significant increases in the level of activation of the following transcription fac-
tors; AP2, AR, CRE/ATF1, CREB, E2F1-5, E2F6, EGR, GATA, HNF-1, ISRE, Myc-Max, NF-1, NFkB, 
p53, PPAR, SMAD 2/3, SP1, TRE/AP1, and YY1. Following erythrocyte membrane isolation, protein 
complexes were undissolved, but denatured. The protein complex formed was resistant to heat and 
detergent. Trypsin and sonication were used in order to break this complex; the complex dissolved and 
erythrocyte membrane proteins were released in SDS-PAGE.
Conclusion: ABS established a very fast and solid protein web, and increased the level of transcription 
factor activation. Therefore the cellular effects of ABS could be related to different intracellular bio-
logical pathways. (Turk J Hematol 2011; 28: 276-85)
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Ankaferd® Blood Stopper (ABS) is comprised of 
a standardized herbal mixture of Thymus vulgaris, 
Glycyrrhiza  glabra,  Vitis  vinifera,  Alpinia  officina-
rum, and Urtica dioica. Each of these herbs has an 
effect  on  endothelium,  blood  cells,  angiogenesis, 
cell proliferation, vascular dynamics, and molecular 
mediators [1,2]. ABS has been historically used as a 
hemostatic  agent  in  traditional  Turkish  medicine 
[3,4]. ABS’s basic mechanism of action is the forma-
tion of an encapsulated protein network that pro-
vides a focal point for vital erythrocyte aggregation 
[1,2]. ABS-induced protein network formation with 
blood cells, particularly erythrocytes, is involved in 
the  physiological  primary  and  secondary  hemo-
static systems without an unbalanced activation of 
individual coagulation factors. This unique mecha-
nism is an advantage of ABS, as compared to other 
hemostatic agents. Exposure to ABS in in the topical 
endothelial  injury  area  provides  a  physiological 
hemostatic effect, together with tissue oxygenation, 
but  without  prothrombotic  pathological  activation 
of any clotting factor [1,2,5,6]. ABS causes encapsu-
lated protein web formation, which induces eryth-
rocyte aggregation via the interactions of fibrinogen 
gamma and red blood cells [1]. 
There are distinct and important molecular com-
ponents  of  the  ABS-induced  hemostatic  network. 
Vital  erythroid  aggregation  occurs  with  spectrin-
ankyrin and actin proteins on the membranes of red 
blood  cells.  Essential  erythroid  proteins  (ankyrin 
recurrent  and  FYVE  bundle-containing  protein  1, 
spectrin  alpha,  actin  depolymerizing  factor,  LIM 
bundle and actin-binding subunit 1 isoform a, LIM 
bundle  and  actin-binding  subunit  1  isoform  b, 
NADP-dependent malic enzyme, NADH dehydroge-
nase (ubiquinone) 1 alpha subcomplex, mitochon-
drial  NADP  (+)-dependent  malic  enzyme  3,  ribu-
lose  bisphosphate  carboxylase  large  chain,  and 
maturase K) and the required ATP bioenergy (ATP 
synthase, ATP synthase beta subunit, ATP synthase 
alpha subunit, ATP-binding protein C12, TP synthase 
H+ transporter protein, ADF, and alpha-1, 2-glycos-
yltransferase ALG10-A) are included in the ABS pro-
tein library [7]. The physiological protein profile of 
red blood cell membranes (Figure 1) and the ABS 
protein library are similar [7]; therefore, vital ery-
throid  aggregation  is  crucial  to  the  ABS-induced 
hemostatic network.
ABS is a hemostatic agent that can be used effec-
tively in clinical practice to control external bleeding, 
dental and periodontal hemorrhaging, dermal bleed-
Özet
Amaç: Ankaferd BloodStopper® (ABS) bir bitkisel karışımıdır ve geleneksel Türk tıbbında uzun yıl-
lardır kullanılmaktadır. ABS, T. vulgaris, G. glabra, V. vinifera, A. officinarum ve U. dioica bitkilerinin 
standartlaştırılmış en uygun karışımını ihtiva etmektedir. Temel etki mekanizması vital fizyolojik erit-
rosit birikimlerinin protein ağı yapısı oluşturmasıdır. Hemostatik etkileri in vivo ve in vitro çalışmalar-
da gösterilmiştir. ABS dış kanamalarda ve diş kanamalarında kontrollü klinik çalışmaları yapılmış 
güvenlik ve etkinlik raporları ile tescillenmiştir. Transkripsiyon faktörleri potansiyel olarak hemostatik 
ve diğer olası etkilerin merkezinde yer alabilir ve ABS uygulamalarından etkilenebilirler. 
Yöntem ve Gereçler: Bu çalışmada, ABS’nin endotelde ve olası transkripsiyon faktörleri değişimini 
HUVEC’lerde (insan umbilikal ven endotelyal hücreleri) ve eritrosit membran profilleri üzerindeki 
etkilerinin incelenmesi amaçlanmıştır. ABS, HUVE hücrelerine (75cm2 yüzeyde; ~%75 dolulukta), 5 
μL ve 50 μL hacimlerde 5 ve 15 dakika uygulanmıştır. 
Bulgular: Transkripsiyon faktörlerinden AP2, AR, CRE/ATF1, CREB, E2F1-5, E2F6, EGR, GATA, 
HNF-1, ISRE, Myc-Max, NF-1, NFkB, p53, PPAR, SMAD 2/3, SP1, TRE/AP1, YY1’in aktivasyonların-
da  artış  gözlenmiştir.  Kandan  eritrosit  membranı  izolasyonundan  sonra,  protein  komplekslerinin 
denatürasyona rağmen çözünmemiş halde kalmaktadır ve bu kompleksler sıcaklığa ve deterjana daya-
nıklıdır. Sonikasyon ve tripsin muamelesinden sonra bu kompleksin ayrıştığı ve eritrosit membran 
proteinlerinin ortaya çıktığı SDS-PAGE’de gözlemlenmiştir.  
Sonuç: Sonuçlar gözönüne alındığında hemostatik ajan ankaferd’in kanamaları durdururken çok hızlı 
ve sağlam bir ağ oluşturmaktadır ve uygulandığı bölgedeki hücrelerin içinde de etkili olup transkrip-
siyon faktörleri seviyelerini de etkileyerek birçok biyolojik mekanizmalar üzerinde etkili olabilir.
(Turk J Hematol 2011; 28: 276-85)
Anahtar kelimeler: Ankaferd®, endotel, transkripsiyon faktörleri, eritrosit
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The hemostatic effects of ABS have been observed in 
vitro and in vivo [12-18]. Use of ABS as a hemostatic 
agent in external hemorrhages and in dental treat-
ment in humans provided the first data showing that 
ABS was safe and effective in humans [9]. A phase I 
randomized,  double-blind  crossover  placebo-con-
trolled clinical study performed with healthy volun-
teers reported that topical ABS usage was safe [20]. 
In terms of the potential use of ABS, transcription 
factors [21-23] may be novel factors that play a role 
in the hemostatic and other pleiotropic effects of 
ABS. Hence, the present study aimed to investigate 
the  effects  of  ABS  on  endothelium,  and  possible 
transcription  factor  changes  in  HUVEC  (human 
umbilical vein endothelial cells) and the erythrocyte 
membrane profile. We also intended to observe the 
interrelationships  between  protein  profile  of  ABS 
and  the  ABS-induced  bond  forming  structures 
between red blood cells.
Materials and Methods
The production, control, and analyses methods 
of ABS have been previously described [20]. ABS is 
available in 3 pharmaceutical forms: ampoule, pad, 
and spray:
1.  Ankaferd® Blood Stopper 2-mL ampoule
2.  Ankaferd® Blood Stopper pad
  · 2.5×7 cm (3 mL)
  · 5×7.5 cm (10 mL)
  · 20×20 cm (100 mL)
3.  Ankaferd® Blood Stopper spray
  · 5 mL
  · 10 mL
  · 25 mL
  · 50 mL
  · 200 mL
The quantities of the active ingredients in each 
pharmaceutical form are shown in Tables 1 and 2.
The effects of ABS on transcription factors and 
the erythrocyte protein profile in HUVEC endotheli-
um  were  examined.  ABS  (5  μL  and  50  μL)  was 
administered  to  HUVEC  (cellular  properties;  in   
75  cm2;  ~75%  fullness)  for  5  min  and  15  min. 
Nucleus isolation of HUVEC was performed using a 
nuclear extraction kit (Marligen Biosciences, USA) 
and the level of activity of the following transcription 
Yılmaz et al.
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Table 1. Ingredients in the Ampoule and Pad Forms of ABS
Active ingredient  Quantity (mg)
  Ampoule  Pad
  2 mL  2.5×7 cm  5×7.5 cm  20×20 cm 
    (3 mL)  (10 mL)  (100 mL)
Urtica dioica1  0.12  0.18  0.6  6
Vitis vinifera2  0.16  0.24  0.8  8
Glycrrhiza glabra2  0.18  0.27  0.9  9
Alpinia officinarum2  0.14  0.21  0.7  7
Thymus vulgaris3  0.10  0.15  0.5  5
1Dried root extract, 2dried leaf extract, 3dried grass extract
Table 2. Ingredients in the Spray Form of ABS
Active ingredient  Quantity 
  (mg/mL)
Urtica dioica1  0.06
Vitis vinifera2  0.08
Glycrrhiza glabra2  0.09
Alpinia officinarum2  0.14
Thymus vulgaris3  0.10
1Dried root extract, 2dried leaf extract, 3dried grass extract Figure 1. The red blood cell membrane and and its proteins
This figure was originally published in Blood. Low, P. S. Blood 2009; 113: 5372-3
© The American Society of Hematology (with permission)
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tion factor profiling kit (20-plex) (Marligen Biosciences, 
USA)  and  examined  (Luminex  100,  Marligen 
Biosciences, USA) according to the manufacturer’s 
instructions; AP2 (activating protein 2), AR (androgen 
receptor), CRE-ATF1 (cyclic AMP response element 
or  activating  transcription  factor  1),  CREB  (cyclic 
AMP  response  element-binding  protein),  E2F1-5, 
E2F6, EGR (early growth response), GATA (globulin 
transcription factor), HNF1 (hepatocyte nuclear fac-
tor-1),  ISRE  (interferon  (IFN)-stimulated  response 
element),  Myc-Max,  NF1  (nuclear  factor-1),  NF-κB 
(nuclear factor kappa B), p53 (protein 53 or tumor 
protein 53), PPAR (peroxisome proliferator-activated 
receptor),  SMAD2/3,  SP1,  TRE/AP1  (TPA  response 
element/activating protein 1), and YY1 (Yin Yang 1). 
Two  independent  experiments  were  performed  in 
duplicate with SD when indicated.
In order to examine the erythrocyte protein web 
10  mL  of  human  blood  was  eluted,  according  to 
density gradients (Ficoll analysis solution d=1.077). 
The  erythrocytes  were  washed  3  times  with  PBS 
and ABS was administered in doses of 25 μL/mL,   
50 μL/mL, and 150 μL/mL. Erythrocyte membrane 
isolation was performed and examined in 10% SDS-
PAGE.
Results
Interestingly, it is microscopically observed that 
the endothelial cells arised from the plastic surface 
and adhered to each other upon the ABS applica-
tion to the HUVEC. In response to low dose ABS   
(5 μL) treatment for 15 min, all of the transcription 
factors reached to the highest level of activity, but at 
the higher dose (50 μL) the activation level is not 
further enhanced. The level of activation of the fol-
lowing transcription factors increased significantly 
in  response  to  ABS;  AP2,  AR,  CRE-ATF1,  CREB, 
E2F1-5,  E2F6,  EGR,  GATA,  HNF1,  ISRE,  Myc-Max, 
NF1, NF-κB, p53, PPAR, SMAD2/3, SP1, TRE/AP1, and 
YY1 (Figures 2 and 3 indicate the increments of the 
transcription  factors  and  the  dose  and  exposure 
time of ABS). 
During the ABS administration to the erythrocyte 
suspension,  being  dose-dependent  also,  cellular 
adhesions to each other were observed. Likewise, 
cellular  unifications  formed  in  different  dosages 
were having different sizes of pellets. Following the 
erythrocyte membrane isolation, protein complex-
es  were  undissolved,  but  denatured.  The  protein 
complex that formed was resistant to heat (100°C) 
and detergent. Trypsin and sonication were used in 
order to break this complex; the complex dissolved 
and erythrocyte membrane proteins were released 
in SDS-PAGE (Figures 4 and 5). 
Discussion
The present study investigated the effects of ABS 
on transcription factors and the erythrocyte protein 
profile  in  HUVEC  endothelium.  ABS  effectively 
stopped bleeding due to rapid formation of a com-
plex  between  the  cells  and  because  the  bond 
formed  within  the  complex  was  very  strong.  We 
think that ABS is very effective at low doses (5 μL) 
not only outside cells, but inside as well, and can 
affect many molecular mechanisms in endothelial 
cells. The level of activity of the transcription factors 
investigated  in  the  present  study  (AP2,  AR,  CRE-
ATF1, CREB, E2F1-5, E2F6, EGR, GATA, HNF1, ISRE, 
Myc-Max,  NF1,  NF-κB,  p53,  PPAR,  SMAD2/3,  SP1, 
TRE/AP1,  and  YY1)  significantly  increased  in 
response to ABS (Figures 2 and 3). These transcrip-
tion  factors  regulate  a  wide  variety  of  biological 
functions, including hemostasis, infection, cellular 
proliferation, and inflammation (Table 3). 
Numerous  studies  reported  the  hemostatic 
effects of topical ABS in the animals with normal 
[10,12,14,16-18] and defective hemostasis [15,24], 
Yılmaz et al.
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Figure 2. Transcription Factor Profile After Ankaferd® Treatment
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ment of this hemostatic product. The effects of ABS 
on hemostatic parameters have also been searched 
[2,6,25].  When  added  to  plasma  or  serum  ABS 
induced rapid formation of a protein network and 
erythrocyte aggregation. The levels of coagulation 
factors  II,  V,  VII,  VIII,  IX,  X,  XI,  and  XIII  were  not 
affected by the administration of ABS. Plasma fibrin-
ogen activity and antigen levels decreased following 
the administration of ABS, along with an increase in 
thrombin time. Total protein, albumin, and globulin 
levels decreased after administration of ABS. The 
researchers suggested that ABS stimulates the for-
mation  of  an  encapsulated  protein  network  that 
provides a focal point for erythrocyte aggregation 
[2,6,25].
The short-term hematological and biochemical 
safety  of  oral  systemic  ABS  in  rabbits  have  been 
reported [13]. Acute mucosal toxicity, hematotoxic-
ity, hepatotoxicity, nephrotoxicity, and biochemical 
Yılmaz et al.
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Figure 4. Microscopic View of Erythrocytes Following ABS Treatment
Figure 5. Sds-Page of Abs-Treated Erythrocytes. Lanes 1-4: Trypsin 
and Sonication After Heat (100°C) and Detergent Treatment. Lane 5:   
Erythrocyte Membrane Proteins Treated with Heat and Detergent
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Figure 3. Transcription Factor Profile After Ankaferd® Treatment
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Table 3. Selected Functions of the Studied Transcription Factors in HUVEC That Were Affected by ABS
Transcription factor  Selected Functions
AP2   AP2 is a critical regulator of gene expression during embryogenesis, and has been implicated in  
  tumorigenesis [19,36,37].
AR  AR is a member of the nuclear receptor superfamily, members of which function as ligand-inducible  
  transcription factors that mediate expression of target genes in response to ligands specific to each receptor,   
  including steroids, retinoids, vitamin D, and thyroid hormone [38].
CRE-ATF1   CRE-ATF1 is a transcriptional activator, and one of many transcription factors that bind a consensus  
  sequence (5’-TGACGTCA) [39].
CREB   The CREB assay detects transcription factors that are responsive to intracellular levels of cyclic AMP . The  
  CREB-binding element is an important indicator of signals propagated by hormones, growth factors, and  
  neurotransmitters. CREB-binding proteins also function in growth factor-dependent cell survival, glucose  
  homeostasis, and in learning and memory [40].
E2F1-5, E2F6   E2F is a group of genes that codifies a family of transcription factors (TF) in higher eukaryotes. Three of  
  them are activators: E2F1, E2F2, and E2F3a. Six others act as suppressors: E2F3b and E2F4-8. All are involved   
  in cell cycle regulation and DNA synthesis in mammalian cells. E2Fs as TFs bind to the TTTCGCGC  
  consensus binding site in the target promoter sequence [41].
EGR   Four members of the EGR family are well known: Egr1 (ZNF225, ZIF268, NGFI-A, Krox-24); Egr2 (Krox-20);  
  Egr3; Egr4 (NGFI-C). EGR-1 and EGR-2 encode nuclear proteins with zinc finger DNA-binding domains and  
  immediate-early genes in T-cell activation, and can regulate transcription synergistically with NF-ATc.  
  A correlation between EGR proteins and Wilms' tumors has been reported [42,43].
GATA   The GATA site 5’-TCAGATAAGA-3’ binds GATA transcription factors. GATA transcription factors are  
  transcriptional activators that function via different genes in many different cell and tissue types. There are  
  at least 6 forms of GATA protein. GATA regulates erythroid differentiation, promotes production of erythroid  
  proteins such as spectrin, and is important to the health of red blood cells interacting with urotensin II. [44]
HNF1   Hepatocyte nuclear factors (HNFs) are a group of phylogenetically unrelated transcription factors that  
  regulate the transcription of a diverse group of genes into proteins. These proteins include blood clotting  
  factors, and enzymes and transporters involved in glucose, cholesterol, and fatty acid transport and  
  metabolism [45,46].
ISRE   ISRE is known to induce MHC class I expression in response to IFNs, as well as a region comprising site  
  α/enhancer B, which significantly stimulates constitutive transcription of HLA class I genes. Tumor cells are 
  thought to escape immune surveillance by T cells via suppressing expression of major histocompatibility  
  complex (MHC) class I molecules at their cell surface. ISRE acts as an anti-tumor molecule via acting on  
  this mechanism [47].
Myc-Max  The Myc-Max site 5’-ACCACGTGGT-3’ binds c-Myc/Max heterodimers. Different transcription factors from the  
  bHLH-ZIP class of proteins can form homo- or heterodimers and bind to the Myc-Max site to regulate genes  
  associated with the cell cycle. Activation of myc genes are associated with cancer and there is much  
  evidence that myc plays a major role in the pathogenesis of Burkkitt’s lymphoma [48]. 
NF1  The core nuclear factor-1 (NF-1/CTF-1) binding site 5’-TGGNNNNNNGCCAA-3’ binds to proteins of the NF-1  
  family. NF-1 proteins are transcriptional activators that directly interact with TFIIB and facilitate assembly of  
  basal transcription complexes. NF-1 is expressed in a wide variety of cell types, with the exception of B-cells  
  and T-cells. Chick embryo fibroblasts that over-express NF-1 proteins are resistant to transformation by the  
  nuclear oncogenes jun, fos, junD, myc, and qin, but are readily transformed by cytoplasmic oncogenes such  
  as src, raf, ras, and fps [49].
NF-κB   Complexes comprising homo- or heterodimers of proteins from the NFκB or rel family bind to the NFκB site 
  (5’-AGGGGACTTTCCCA-3’). Transcription factors of the Rel NFκB family are ubiquitous in cells and are 
  activated in response to signals that lead to cell growth, differentiation, inflammation, and apoptosis. NFκB 
  proteins are connected to various signaling pathways that affect important biological responses, which has  
  made them a high priority as pharmaceutical targets [50]. 
p53 (protein 53 or     p53 is important in multi-cellular organisms, regulating the cell cycle and thus such functions as a tumor 
tumor protein 53)   suppression. As such, p53 has been described as the guardian of the genome, the guardian angel gene, and  
  the master watchman, referring to its role in conserving stability by preventing genome mutation [51].
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(7  days)  follow-up  period  [13].  Use  of  ABS  as  a 
hemostatic agent in external hemorrhages and in 
dental treatment in humans provided the first data 
showing that ABS was safe and effective in humans 
[9]. A phase I double-blind, randomized crossover, 
placebo-controlled clinical study with a 5-d wash-
out  period  between  the  crossover  periods  that 
included healthy volunteers reported that ABS was 
safe [20]. Physiological cell-based coagulation was 
clinically  managed  using  topical  ABS  to  prevent 
and treat bleeding associated with many clinico-
pathological states [10,18,26-28]. Erythrocyte mass-
es are critical in the ABS-induced hemostatic pro-
tein  network  (Figures  4  and  5).  Proteins  on  the 
cytoplasmic  surface  of  erythrocyte  membranes, 
including spectrin and actin, are thought to com-
prise  the  red  cell  cytoskeleton.  Actin  added  to 
erythrocyte  ghosts  selectively  associated  with  a 
component at the cytoplasmic surface of the mem-
brane, and actin binding occurred via stimulation 
of actin polymerization (Figure 1). Haznedaroglu et 
al.  [29]  proposed  that,  platelets  are  not  directly 
affected, but leukocyte activation is evident follow-
ing the ABS exposure to whole blood according to 
the  ultrastructural  scanning  electron  microscopic 
(SEM) morphological analyses [29]. Further investi-
gations  are  needed  to  elucidate  that  vital  issue 
since cellular hemostasis is a critical component of 
ABS hemostatic effects.
In the present study, GATA activity significantly 
increased  following  the  administration  of  ABS. 
GATA regulates erythroid differentiation, promotes 
production of erythroid proteins such as spectrin, 
and  is  important  to  the  health  of  red  blood  cells 
(Table 1). 
The  in  vitro  antibacterial  activity  of  ABS  was 
evaluated  against  26  indicator  strains,  including 
gram-positive and gram-negative bacteria, using the 
agar  diffusion  method,  and  was  observed  to  be 
effective against all strains [30,31]. Nisin, a food pre-
servative bacteriocin used as a control, was inactive 
against gram-negative strains. In addition to its high 
inhibitor  activity  against  various  pathogens,  and 
gram-positive and gram-negative bacteria, ABS was 
more stable than nisin at various temperatures and 
in  the  presence  of  enzymes.  The  antimicrobial 
activity of ABS was tested against many pathogens, 
including A. baumannii, E. coli, K. pneumonia, P. 
aeruginosa,  Enterobacter  spp.,  Stenotrophomonas 
maltophilia,  MRSA,  methicillin-resistant  coagulase 
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PPAR   The PPAR site, also known as the peroxisome proliferation response element (PPRE), 5’-TGACCTTGACCT-3’  
  binds transcription factors from the PPAR family as homo- and heterodimers. Three PPAR isotypes-PPAR- 
  alpha, PPAR-beta/delta, and PPAR-gamma-have been identified. PPARs have a DNA-binding domain and a  
  ligand-binding domain with specificity for prostanoids, fatty acids, fibrates, and thiazolidinediones. Once  
  activated by ligand binding, PPARs bind to DNA at the peroxisome proliferator response elements (PPREs)  
  within genes and modulate transcription. PPARs display differential tissue distribution with PPAR-alpha and  
  PPAR-gamma, playing a role in the pathogenesis of chronic diseases such as diabetes, obesity, and  
  atherosclerosis. There is substantial evidence that different ligands may determine the specificity of PPARs  
  interaction with particular co-activators, and drugs such as hypolipidemic fibrates and insulin-sensitizing  
  thiazolidinediones (pioglitazone and rosiglitazone) have been developed to modulate their activity [52].
SMAD2/3  SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling  
  pathways. This protein mediates the signal of transforming growth factor (TGF)-beta, and thus regulates  
  multiple cellular processes, such as cell proliferation, apoptosis, and differentiation [53,54].
SP1  Sp1 is a human transcription factor involved in gene expression in the early development of an organism.  
  SP1 contains a zinc finger protein motif, with which it binds directly to DNA and enhances gene  
  transcription. Sp1 interacts with ATF7IP , ATF7IP2, POGZ, HCFC1, AATF, and PHC2 [55,56].
TRE/AP1   AP1 mediates gene regulation in response to many different physiological and pathological stimuli, including   
  cytokines, growth factors, stress signals, and bacterial and viral infections, as well as oncogenic stimuli. The  
  most widely studied AP1 complex is a c-Jun/c-Fos heterodimer. Studies on genetically modified mice and  
  cells have highlighted the crucial role AP1 plays in a variety of cellular events involved in normal  
  development and neoplastic transformation causing cancer. AP1-binding proteins are targets being  
  considered by the pharmaceutical industry [57,58].
YY1   YY1 plays a fundamental role in normal biologic processes, such as embryogenesis, differentiation,  
  replication, and cellular proliferation. As YY1 expression and function are known to be intimately associated  
  with progression through phases of the cell cycle, the physiologic significance of YY1 activity has recently  
  been applied to models of tumor biology [59].
TJH-ARALIK-2011-4-crossref.indd   34 02.12.2011   10:13negative  Staphylococcus,  vancomycin-susceptible 
Enterococcus, and VRE, and was noted to be active 
against  all  the  isolates,  with  zones  of  inhibition 
between 10 and 18 mm in diameter [32]. In addition 
to ABS’s hemostatic effects in hemorrhagic wound 
healing, its antimicrobial property can also be ben-
eficial, and ABS has the potential to protect against 
various  types  bacterial  pathogens  [31,32].  In  the 
present study, ABS upregulated numerous transcrip-
tion factors (Figures 2 and 3) in endothelial cells that 
play a role in the process of infection and inflamma-
tion in response to a wide variety of pathogens and 
in wound healing, including AR, ISRE, EGR, HNF1, 
NF-κB,  PPAR,  SMAD2/3,  and  YY1  (Table  3).  There 
may be a relationship between transcription factor 
activation and anti-infective activities of ABS. there-
fore, those data in our study represent true basis to 
further search the ‘mechanism of action’ of Ankaferd 
against  distinct  pathogens  and  wound  healing  as 
described in previous in vitro studies [30-32]. 
There are several hypotheses such as decreased 
angiogenesis, increased apoptosis, and interactions 
with tumor hemostasis that attempt to account for 
ABS’s mechanism of action on tumor tissue [8,33-35]. 
The hemostatic action of ABS is correlated with a 
reduction  in  tumor  neo-angiogenesis.  Topical  ABS 
administration  to  gastrointestinal  neoplastic  tissue 
resulted  in  the  control  of  bleeding  and  decreased 
tumor vascularization in rectal and gastric cancers 
[26]. Moreover, there is a close relationship between 
coagulation factor expression and solid tumor pro-
gression, via mechanisms other than angiogenesis. 
In the present study ABS significantly increased the 
level of activity of the following transcription factors; 
AP2, AR, CRE-ATF1, CREB, E2F1-5, E2F6, EGR, ISRE, 
Myc-Max,  NF1,  NF-κB,  p53,  PPAR,  SMAD2/3,  SP1, 
TRE/AP1, and YY1. These regulator molecules affect 
distinct  steps  of  cellular  proliferation,  such  as  cell 
cycle  regulation,  angiogenesis,  signal  transduction, 
apoptosis, inflammation, acute phase reaction, and 
immunity,  and  several  metabolic  molecular  path-
ways  (Table  3).  In  vivo  preclinical  models  will  be 
designed to elucidate the effects of ABS on neoplas-
tic tissue, as described in previous in vitro studies 
[33,34] and in vivo studies on bleeding tumors [8,35]. 
The pleiotropic effects of ABS on vascular endo-
thelium, blood cells, angiogenesis, cellular prolifer-
ation,  vascular  dynamics,  and  cellular  mediators 
are  being  investigated  to  determine  the  potential 
role of ABS in many pathological states, including 
neoplastic  disorders,  infectious  diseases,  and 
inflammation. Our observations in this report about 
the  cellular  effects  of  Ankaferd  may  shed  further 
light on that perspective. 
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